Development of an HIV Rev-dependent dual-reporter cell for anti-HIV drug screenin
开发用于抗 HIV 药物筛选的 HIV Rev 依赖性双报告细胞
基本信息
- 批准号:8296270
- 负责人:
- 金额:$ 7.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-05 至 2013-06-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAcquired Immunodeficiency SyndromeAnti-HIV AgentsAnti-Retroviral AgentsAntibodiesBiological AssayCCR5 geneCell LineCellsChemicalsDependencyDevelopmentExhibitsFlow CytometryGene ExpressionGrantHIVHIV AntibodiesHIV InfectionsHIV Long Terminal RepeatHela CellsHighly Active Antiretroviral TherapyImmuneIn VitroInhibitory Concentration 50LactamaseLentivirus VectorLibrariesLong Terminal RepeatsLuciferasesMeasuresMediatingMethodologyMitogensMulti-Drug ResistanceMutationNoisePharmaceutical PreparationsPreclinical Drug EvaluationProbabilityReagentReporterReporter GenesReportingResearchResearch MethodologyResponse ElementsScreening procedureSignal TransductionSuspension substanceSuspensionsSystemTechnologyTestingTranscriptional ActivationTranslationsUnited States National Institutes of HealthUp-RegulationUrsidae FamilyViralViral Load resultVirusbasecytokinecytotoxicitydrug candidatedrug discoveryhigh throughput screeninginhibitor/antagonistnovelnovel therapeuticsnucleocytoplasmic transportpandemic diseaseprogramspromoterprospectiverepositorytat Proteintranscription factortreatment planning
项目摘要
DESCRIPTION (provided by applicant): HIV/AIDS is a worldwide pandemic afflicting 40 million people, and currently there is no cure. The proposed research is to develop a new reporter cell line to facilitate the discovery of novel anti-HIV drugs. This prospective reporter cell system will employ a Rev-dependent lentiviral vector, which has been shown previously to be highly specific to HIV infection. This novel system will greatly facilitate the development of a novel cell- based drug screening platform. Additionally, by employing two reporters this system can be used in multiple assay formats and would be amenable to high-throughput screens for antiretroviral compounds.
描述(申请人提供):艾滋病毒/艾滋病是一种世界性的流行病,影响着4000万人,目前还没有治愈方法。这项拟议的研究是为了开发一种新的报告细胞系,以促进抗HIV新药的发现。这一未来的报告细胞系统将采用REV依赖的慢病毒载体,该载体已被证明对HIV感染具有高度特异性。这一新系统将极大地促进基于细胞的新型药物筛选平台的开发。此外,通过使用两个记者,该系统可以用于多种检测形式,并将服从于高通量的抗逆转录病毒化合物的筛选。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YUNTAO WU其他文献
YUNTAO WU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YUNTAO WU', 18)}}的其他基金
Mechanisms of PSGL-1 restriction of HIV virion infectivity
PSGL-1限制HIV病毒粒子感染性的机制
- 批准号:
9927218 - 财政年份:2020
- 资助金额:
$ 7.07万 - 项目类别:
Mechanisms of PSGL-1 restriction of HIV virion infectivity
PSGL-1限制HIV病毒粒子感染性的机制
- 批准号:
10366051 - 财政年份:2020
- 资助金额:
$ 7.07万 - 项目类别:
Mechanisms of PSGL-1 restriction of HIV virion infectivity
PSGL-1限制HIV病毒粒子感染性的机制
- 批准号:
10593948 - 财政年份:2020
- 资助金额:
$ 7.07万 - 项目类别:
Validation of the Rev-dependent vector for targeting SIV macrophage reservoirs
针对 SIV 巨噬细胞储库的 Rev 依赖性载体的验证
- 批准号:
8731441 - 财政年份:2014
- 资助金额:
$ 7.07万 - 项目类别:
Validation of the Rev-dependent vector for targeting SIV macrophage reservoirs
针对 SIV 巨噬细胞储库的 Rev 依赖性载体的验证
- 批准号:
9233206 - 财政年份:2014
- 资助金额:
$ 7.07万 - 项目类别:
Development of a novel HIV-1 nuclear localization assay
新型 HIV-1 核定位测定的开发
- 批准号:
8657743 - 财政年份:2014
- 资助金额:
$ 7.07万 - 项目类别:
Validation of the Rev-dependent vector for targeting SIV macrophage reservoirs
针对 SIV 巨噬细胞储库的 Rev 依赖性载体的验证
- 批准号:
9047312 - 财政年份:2014
- 资助金额:
$ 7.07万 - 项目类别:
Development of an HIV Rev-dependent dual-reporter cell for anti-HIV drug screenin
开发用于抗 HIV 药物筛选的 HIV Rev 依赖性双报告细胞
- 批准号:
8138239 - 财政年份:2011
- 资助金额:
$ 7.07万 - 项目类别:
Regulation of Cofilin in HIV-1 Infection of Human CD4 T Cells
Cofilin 在人类 CD4 T 细胞 HIV-1 感染中的调节
- 批准号:
8277404 - 财政年份:2009
- 资助金额:
$ 7.07万 - 项目类别:
Regulation of Cofilin in HIV-1 Infection of Human CD4 T Cells
Cofilin 在人类 CD4 T 细胞 HIV-1 感染中的调节
- 批准号:
7755791 - 财政年份:2009
- 资助金额:
$ 7.07万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 7.07万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 7.07万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 7.07万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 7.07万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 7.07万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 7.07万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 7.07万 - 项目类别: